This was the stock's second consecutive day of gains.

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

Merck (MRK) ended the recent trading session at $78.27, demonstrating a +1.46% swing from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.01% for the ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

Artisan Partners, an investment management company, released its “Artisan Value Fund” first quarter 2025 investor letter. A ...

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights.

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

Amid ongoing uncertainty around funding for the NIH and what it could mean for U.S. innovation, a top Merck executive ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...